-
Mashup Score: 6Disease Overview: Light Chain (AL) Amyloidosis - 27 day(s) ago
Understand the latest information about how Light Chain (AL) amyloidosis might affect you and symptoms to be aware of. This booklet is …
Source: arci.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11Autologous Stem Cell Transplants in AL Amyloidosis - 4 month(s) ago
This booklet discusses the various impacts, considerations, and possible side effects of Autologous Stem Cell Transplants in AL …
Source: arci.orgCategories: General Medicine News, Onc News and JournalsTweet-
Understand the impacts, considerations, & possible side effects of Autologous Stem Cell Transplants (ASCT) in #AL #amyloidosis. Our new booklet gives a foundational understanding of this treatment option and how it may or may not impact patient's lives. https://t.co/eBYZ6ZqnJj
-
-
Mashup Score: 0Birtamimab to Treat AL Amyloidosis - 7 month(s) ago
Dr. Hideki Garren, Chief Medical Officer at Prothena discusses the clinical data supporting the use of birtamimab to treat AL amyloidosis.
Source: CheckRare.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Hideki Garren, MD, PhD, Chief Medical Officer at Prothena, discusses the clinical data supporting using birtamimab to treat AL amyloidosis #checkrare #ALamyloidosis https://t.co/TxyFTkMQsH
-
-
Mashup Score: 0FDA Grants Orphan Drug Designation for Nexcella for Amyloid Light Chain Amyloidosis - 7 month(s) ago
FDA has granted Nexcella’s NXC-201 Orphan Drug Designation for the treatment of AL amyloidosis.
Source: CheckRare.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The U.S. Food and Drug Administration #FDA has recently granted Nexcella’s NXC-201 Orphan Drug Designation #ODD for the treatment of AL amyloidosis #checkrare #ALamyloidosis https://t.co/y9K1pFKsyb
-
-
Mashup Score: 1Birtamimab to Treat AL Amyloidosis - 7 month(s) ago
Dr. Hideki Garren, Chief Medical Officer at Prothena discusses the clinical data supporting the use of birtamimab to treat AL amyloidosis.
Source: CheckRare.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Hideki Garren, MD, PhD, Chief Medical Officer at Prothena, discusses the clinical data supporting using birtamimab to treat AL amyloidosis #checkrare #ALamyloidosis https://t.co/TxyFTkMQsH
-
-
Mashup Score: 5First patient dosed in SAR’514 / IPH6401 Phase 1/2 clinical trial in relapsed/refractory multiple myeloma | Innate Pharma - 10 month(s) ago
Partner Sanofi advances SAR’514 / IPH6401, a trifunctional anti-BCMA NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, to first-in-human clinical trial in relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) Second molecule from Innate’s multi-specific NK cell engager platform ANKET® to progress to…
Source: www.innate-pharma.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 First patient dosed in a phase I/II clinical trial of SAR’514 / IPH6401, a trifunctional anti-BCMA NKp46xCD16 NK cell engager, for the treatment of RRMM and RR light-chain amyloidosis. Read more: https://t.co/iUabCcwo7N #mmsm #myeloma #ALamyloidosis #mednews https://t.co/QdKZPPPXcN
-
-
Mashup Score: 12AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review - 1 year(s) ago
Abstract Amyloid light chain (AL) amyloidosis is a rare, debilitating, often fatal disease. Symptoms of cardiomyopathy are common presenting features, and patients often are referred to cardiologis…
Source: JACC: CardioOncologyCategories: Expert Picks, Latest HeadlinesTweet-
ICYMI: Read this #JACCCardioOnc state-of-the-art review on everything #cardiologists need to know about AL #amyloidosis: suspecting, diagnosing, treating their patients, including emerging novel treatments. https://t.co/89dYdE8VDl #ALAmyloidosis #BetterOutcomes #CardioOnc https://t.co/deixUrR3fa
-
-
Mashup Score: 3Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial - 1 year(s) ago
Abstract Background Patients with amyloid light chain amyloidosis and severe cardiac dysfunction have a poor prognosis. Treatment options that induce rapid and deep hematologic and organ responses,…
Source: JACC: CardioOncologyCategories: Expert Picks, Latest HeadlinesTweet-
Post hoc analyses of ANDROMEDA published in #JACCCardioOnc shows #daratumumab, bortezomib, cyclophosphamide & dexamethasone improve hematologic & organ response in AL #amyloidosis, in all cardiac stages. https://t.co/JgqutzfeYl #JACCCardioOnc #CardioOnc #ALAmyloidosis https://t.co/BVlkvVd8Zq
-
-
Mashup Score: 3The Multiple Myeloma Daily - 1 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/TFX1NiY108 Thanks to @MyelomaEurope @PBeatingCancer #myeloma #alamyloidosis
-
-
Mashup Score: 4
Join the conversation with Camille Pope, PharmD, RPh, from Acclinate, and Kathi Luis from the Amyloidosis Foundation as they discuss how AL Amyloidosis affects communities of color and how the Amyloidosis Foundation supports patients, their families, and caregivers.
Source: ZoomCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join the conversation with Camille Pope from Acclinate and Kathi Luis from the Amyloidosis Foundation as we discuss how AL Amyloidosis affects communities of color. Register here: https://t.co/Ps5vhIMXav #ALamyloidosis #amyloidosis #inclusion https://t.co/8Gl5MzMqR0
-
Understand the latest information about how Light Chain (#AL) #amyloidosis might affect you and symptoms to be aware of. This booklet is a companion booklet to our Treatment Overview: Light Chain (AL) Amyloidosis booklet: https://t.co/hBGLVdcE3w